Non-small cell lung cancer
Conditions
Interventions
Experimental group:Icotinib increase
Control group:Conventional dosage of Icotinib
Sponsors
Guangxi Medical University Affiliated Tumor Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients with stage IIIB/IV newly treated non-small cell lung adenocarcinoma (or mixed adenocarcinoma components) who are not suitable for radical surgery or radiotherapy confirmed by histopathology, patients have received adjuvant chemotherapy and stopped the drug for more than 6 months can be selected ; 2. EGFR gene detection 19 exon mutation; 3. Aged >= 18 years; 4. ECOG 0-4 points; 5. Asymptomatic brain metastases; 6. There is imaging to assess the lesion, according to the evaluation standard of solid tumor efficacy (RECIST 1.1), there is at least one single-path measurable lesion, and the longest diameter is measured by spiral CT >= 10 mm (for any lesion that has received radiotherapy, it cannot as a target lesion); 7. Women of childbearing age must take a pregnancy test within 7 days before starting treatment and the result is negative; 8. Males of childbearing age need to take contraceptive measures during the period of surgical sterilization or treatment and within 3 months after the end.
Exclusion criteria
Exclusion criteria: 1. There are serious or uncontrollable systemic diseases (such as interstitial pneumonia or abnormal liver function); 2. Suffer from any other malignant tumors within five years (except for fully cured cervical carcinoma in situ or basal cell or squamous cell skin cancer); 3. Have a clear history of neurological or mental disorders, including epilepsy or dementia; 4. Pregnant or lactating women; 5. Evidence that there are any other important clinical abnormalities or laboratory test results that make the patient unsuitable to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival;Overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease control rate;Objective response rate;Toxic side effects; | — |
Countries
China
Contacts
Public ContactZeng Aiping
Guangxi Medical University Affiliated Tumor Hospital
Outcome results
None listed